Clinical Trial Update: An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

View source ↗

Summary

This completed observational study (GUARD-C) looked at predicting adverse events in chronic hepatitis C patients treated with a long-acting interferon plus riba…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Status: COMPLETED